Among 40 patients with advanced NSCLC who relapsed after standard therapy treated with 1200 mg of M7824, the ORR was 40.7% for PD-L1-positive patients and 71.4% for patients with high PD-L1 expression (169). Here, CD274 is linked to non-small cell lung carcinoma.